NIKKEI 225
38,703.51 +213.34 (+0.55%) HANG SENG
18,476.80 +51.84 (+0.28%) CRUDE OIL
75.61 +1.54 (+2.08%) GOLD FUTURES
2,392.70 +17.20 (+0.72%) DOW
38,880.36 +73.03 (+0.19%) Bitcoin GBP
55,445.12 -32.81 (-0.06%)
NVAX Jan 2025 22.500 call
| Previous close | 5.80 |
| Open | 6.53 |
| Bid | 5.35 |
| Ask | 5.75 |
| Strike | 22.50 |
| Expiry date | 2025-01-17 |
| Day's range | 5.15 - 6.65 |
| Contract range | N/A |
| Volume | |
| Open interest | 694 |
- Yahoo Finance Video
Novavax stock rises on COVID vaccine delivery projections
Shares of Novavax (NVAX) are surging after the company announced it will meet delivery expectations for the fall COVID vaccine push. All COVID vaccines will use the JN.1 strain, part of the Omicron subvariant family. The FDA also set a final date for fully approving the company's COVID vaccine beyond its emergency use authorization. Anjalee Khemlani joins the Morning Brief to break down the details. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This article was written by Gabriel Roy
Barrons.comNew Covid Boosters Get a Thumbs-Up From FDA. Vaccine Stocks Are Wavering.
Drugmakers are aiming to launch this year’s shots by the beginning of September but have been waiting on the FDA to decide which strain of the virus to target. At their meeting on Wednesday, the FDA’s advisers nevertheless recommended that this year’s shots target JN.1, saying they expect a JN.1 shot to offer sufficient protection against the strain’s descendants.
Investor's Business DailyNovavax, With A 369% Gain, Tears Ahead Again On A Key FDA Move
Novavax stock zipped to a nearly two-year high Thursday after the FDA set a potential approval date for its Covid vaccine in April.
